BPC-157 vs TB-500: Research Profile Comparison
BPC-157 and TB-500 are frequently discussed together in musculoskeletal research literature, and are sometimes assumed to be interchangeable. Structurally and mechanistically, they are distinct compounds studied through different research lenses.
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | BPC-157Synthetic 15-amino-acid fragment derived from a protein found in gastric juice | TB-500Synthetic fragment of thymosin beta-4, a naturally occurring protein |
| Class | BPC-157Body-protection compound (BPC) family | TB-500Actin-regulating peptide fragment |
| Primary research focus | BPC-157Gastrointestinal protection; musculoskeletal and tendon-ligament research | TB-500Cell migration, angiogenesis, and wound-model research |
| Proposed mechanism | BPC-157Modulates growth factor pathways and nitric oxide signalling in preclinical models | TB-500Regulates actin polymerisation, implicated in cell motility in tissue-injury models |
| Stability profile | BPC-157Reported to be relatively stable across a range of conditions in preclinical work | TB-500Similar handling considerations to other short peptide fragments — see our storage guide |
Takeaway
Both are studied in tissue-injury models but through different proposed mechanisms — BPC-157 research centres on gastroprotective and growth-factor pathways, TB-500 research centres on actin regulation and cell migration. Treat published comparisons of the two with appropriate scepticism; head-to-head preclinical data is limited.
Research-profile comparison for laboratory reference only — not a usage or combination guide. See our legal & compliance hub for the regulatory position on either compound.
Common Questions
Are BPC-157 and TB-500 the same thing?
No. They are structurally unrelated. BPC-157 is a 15-amino-acid sequence derived from a protein found in gastric juice; TB-500 is a fragment of thymosin beta-4. They appear together in the same preclinical literature because both are studied in tissue models, not because they are variants of one compound.
Why are BPC-157 and TB-500 so often discussed together?
Both appear in the same body of preclinical musculoskeletal and wound-model literature, which leads to them being grouped in secondary sources and forum summaries. That grouping reflects a shared research context rather than a shared mechanism — the proposed pathways are different.
Is there head-to-head research comparing BPC-157 and TB-500?
Direct comparative preclinical data is limited. Most published work studies each compound separately against a control, not against the other, which means any ranking of the two you encounter online is usually inference rather than measurement.
Does PepcoLab sell TB-500 as a standalone compound?
Not as a standalone vial. TB-500 appears only within the BPC-157 / TB-500 Blend and GLOW in our catalogue, which is why there is no standalone TB-500 link on this page. You can see what we do stock, with the batch certificate for each, on the products page.